|
A phase 3, randomized, double-blind study of luspatercept (ACE-536) in patients (pts) with Revised International Prognostic Scoring System (IPSS-R) very low- to intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts (RS) who require red blood cell (RBC) transfusions: The MEDALIST trial. |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Abbvie |
Consulting or Advisory Role - Celgene; Incyte; Novartis |
Speakers' Bureau - Incyte; Janssen Scientific Affairs; Novartis |
Research Funding - Celgene (Inst); Eleos (Inst); GlaxoSmithKline (Inst); Incyte (Inst) |
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Celgene; Incyte; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Celgene |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
|
Stock and Other Ownership Interests - Affymetrix; Celgene; Gilead Sciences |
|
|
Employment - Acceleron Pharma |
Stock and Other Ownership Interests - Acceleron Pharma |
|
|
Honoraria - Amgen; Celgene; CTI; Janssen; Trillium Therapeutics |
Consulting or Advisory Role - Amgen; Celgene; CTI; Janssen; Trillium Therapeutics |
Research Funding - Celgene |
Patents, Royalties, Other Intellectual Property - Celgene |
Travel, Accommodations, Expenses - Celgene; Trillium Therapeutics |